Axovant is founded and financed by Roivant and its CEO Vivek Ramaswamy, whose central strategy is to buy drugs that have been abandoned or shelved by big pharma and successfully bring them to market.
formerly known as Axovant and one of the 'vant' companies originally founded by entrepreneur Vivek Ramaswamy. Sio's board of directors has decided it is time to call it quits and abandon the ...
Vivek Ganapathy Ramaswamy is an American politician and entrepreneur who has walked an impressive journey from academia to becoming one of the most successful entrepreneurs and a presidential ...
Industries showering Trump with cash included Big Oil, Big Tech, Big Pharma, Big Tobacco, Wall Street, crypto and private prison interests, and more. Many of the corporate donors are poised to win ...
Is the controversy around Robert Kennedy actually an economic lesson for us all about the reason people use words like ‘big pharma’ and ‘big business’? David contrasts the strategy of ...
Robert F. Kennedy attempted Thursday to score a cheap political point against Senator Bernie Sanders by accusing the independent Vermont lawmaker of being bought out by the pharmaceutical industry ...
Goldman Sachs analyst warns 340B reforms could shift profits to biopharma, benefiting companies like Merck and Gilead. Proposed Medicaid cuts may create risks for biopharma, impacting drugs like ...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...
Former presidential candidate Vivek Ramaswamy is calling out the national security risk of having a generation dependent on China as U.S. students fall behind in the classroom. "75% of eighth ...
Vivek Ramaswamy, the former co-leader of the Department for Government Efficiency, was asked during an appearance on Fox News ...
Vivek Ramaswamy was asked if Elon Musk fired him from President Donald Trump's Department of Government Efficiency (DOGE) after Ramaswamy confirmed he was leaving his former role as co-head of the ...